Gut Microbiome in Chronic Kidney Disease
- PMID: 28343357
- DOI: 10.1007/s11906-017-0727-0
Gut Microbiome in Chronic Kidney Disease
Abstract
With over 100 trillion microbial cells, the gut microbiome plays important roles in both the maintenance of health and the pathogenesis of disease. Gut microbiome dysbiosis, resulted from alteration of composition and function of the gut microbiome and disruption of gut barrier function, is commonly seen in patients with chronic kidney disease (CKD). The dysbiotic gut microbiome generates excessive amounts of uremic toxins, and the impaired intestinal barrier permits translocation of these toxins into the systemic circulation. Many of these uremic toxins have been implicated in the progression of CKD and increased cardiovascular risk. Various therapeutic interventions have been proposed that aim to restore gut microbiome symbiosis. If proven effective, these interventions will have a significant impact on the management of CKD patients. In this review, we discuss the consequences of gut microbiome dysbiosis in the context of CKD, discuss the consequences of gut dysbiosis, and highlight some of the recent interventions targeting the gut microbiome for therapeutic purposes.
Keywords: Cardiovascular disease; Chronic kidney disease; Dysbiosis; Microbiome; Uremic toxin.
Similar articles
-
Gut microbiome in chronic kidney disease: challenges and opportunities.Transl Res. 2017 Jan;179:24-37. doi: 10.1016/j.trsl.2016.04.007. Epub 2016 Apr 30. Transl Res. 2017. PMID: 27187743 Free PMC article. Review.
-
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.Am J Kidney Dis. 2016 Mar;67(3):483-98. doi: 10.1053/j.ajkd.2015.09.027. Epub 2015 Nov 15. Am J Kidney Dis. 2016. PMID: 26590448 Free PMC article. Review.
-
The Impact of CKD on Uremic Toxins and Gut Microbiota.Toxins (Basel). 2021 Mar 31;13(4):252. doi: 10.3390/toxins13040252. Toxins (Basel). 2021. PMID: 33807343 Free PMC article. Review.
-
[Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].Zhongguo Zhong Yao Za Zhi. 2017 Jul;42(13):2425-2432. doi: 10.19540/j.cnki.cjcmm.20170609.014. Zhongguo Zhong Yao Za Zhi. 2017. PMID: 28840678 Review. Chinese.
-
Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.Toxins (Basel). 2021 May 19;13(5):361. doi: 10.3390/toxins13050361. Toxins (Basel). 2021. PMID: 34069405 Free PMC article. Review.
Cited by
-
Dietary Phosphorus Levels Influence Protein-Derived Uremic Toxin Production in Nephrectomized Male Rats.Nutrients. 2024 Jun 8;16(12):1807. doi: 10.3390/nu16121807. Nutrients. 2024. PMID: 38931160 Free PMC article.
-
Clostridioides difficile Infection in Chronic Kidney Disease-An Overview for Clinicians.J Clin Med. 2021 Jan 7;10(2):196. doi: 10.3390/jcm10020196. J Clin Med. 2021. PMID: 33430465 Free PMC article. Review.
-
The role of the gut microbiota and its metabolites: a new predictor in diabetes and its complications.Eur J Med Res. 2025 Jul 9;30(1):601. doi: 10.1186/s40001-025-02824-9. Eur J Med Res. 2025. PMID: 40635093 Free PMC article. Review.
-
The effect of gut microbiota dysbiosis on patients with preeclampsia.Front Cell Infect Microbiol. 2023 Jan 4;12:1022857. doi: 10.3389/fcimb.2022.1022857. eCollection 2022. Front Cell Infect Microbiol. 2023. PMID: 36683689 Free PMC article.
-
Shenqi Yanshen Formula (SQYSF) protects against chronic kidney disease by modulating gut microbiota.Bioengineered. 2022 Mar;13(3):5625-5637. doi: 10.1080/21655979.2021.2023789. Bioengineered. 2022. PMID: 35184655 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical